Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Predictors of 90-day mortality in elderly and unfit AML patients treated with single-agent hypomethylating agents or in combination with venetoclax

View Full Paper
Ask AI
Bookmark
Share

Authors

MNMelissa Francoise NeumannDMDavid MuellerJCJ.M. Cho

Discussion

Loading...

Member takes

Overview

Retrospective cohort study identifies predictors of 90-day mortality in elderly AML patients treated with hypomethylating agents and venetoclax, suggesting clinical implications.

Key Points

  • The aim is to identify predictors of 90-day mortality in elderly AML patients receiving hypomethylating agents with or without venetoclax.
  • Retrospective cohort study conducted from 2016 to 2025
  • Analysis of 338 AML patients treated with HMA ± VEN induction
  • Univariate analysis to evaluate 100 variables for correlation with mortality risk
  • Multivariable logistic regression model to identify independent predictors
  • Data from Northwell Health electronic medical records
  • Overall 90-day mortality rate was 34% among 338 patients
  • Identified independent predictors include KMT2A rearrangement, infection on day 1, and ECOG performance status
  • WBC count ≥ 25 × 10⁹/L significantly linked to early mortality
  • TP53 mutation status was not significantly associated with 90-day mortality

Cite This Study

Neumann et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d608https://doi.org/10.1182/blood-2025-5166
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prolonged venetoclax (VEN) plus hypomethylating agent (HMA) therapy in non-promyelocytic AML: A single-centre retrospective cohort study2025
  2. 2Predictors of early mortality in Acute Myeloid Leukemia: A population based analysis using SEER data.2025
  3. 3Genetic risk model to predict outcomes for AML treated with HMA and venetoclax2025
  4. 4A multicenter real-world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN/HMA by 2022 and 2024 ELN risk stratifications: An analysis from the MARROW consortium2025
  5. 5Abstract 5429: REAL-AML: Real-world predictors of early mortality and treatment inequities in acute myeloid leukemia across a multi-institutional U.S. cohort.2026